ForteBio Launches New Dip and Read Anti-FLAG Biosensor to Facilitate Protein Research and Drug Development
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130212:nBw126653a PORT WASHINGTON, N.Y.--(Business Wire)-- ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Dip and Read Anti-FLAG Biosensor for use on the company`s Octet and BLItz instrumentation systems. The new biosensor enables researchers to quickly and easily detect FLAG-tagged recombinant proteins for their quantitation and kinetic characterization, which are key steps in drug development. http://mms.businesswire.com/bwapps/mediaserver/ViewMedia?mgid=357970&vid=4 The Dip and Read(TM) Anti-FLAG Biosensor for use on ForteBio's Octet(R) and BLItz(TM) instrumentation systems enables researchers to quickly and easily detect FLAG-tagged recombinant proteins for their quantitation and kinetic characterization. "FLAG is a commonly used affinity peptide tag to enable protein detection and purification," said Christopher Silva, vice president of marketing for Pall's ForteBio division. "However, traditional methods for evaluating FLAG-tagged proteins rely on time-consuming, analytical methods, which can slow down drug discovery and development. Our new Anti-FLAG Biosensor, together with the BLItz instrument platform`s ease of use or the Octet system`s high throughput, is designed to greatly accelerate laboratory workflow, reduce time to results and increase cost-efficiency." The biosensor is pre-immobilized with Sigma-Aldrich`s well-established, high-affinity ANTI-FLAG M2 antibody, which has been cited in more than 30,000 journal articles over the last two decades. The high specificity of the antibody-based biosensor enables the direct quantitation of FLAG-tagged analytes in crude lysates, column eluents, cell lysates and cell culture supernatants. Mr. Silva added that the new biosensor is intended to address strong demand for direct capture of FLAG-tagged proteins among ForteBio`s Octet customers. It also should further broaden the appeal of the BLItz instrument platform - which enables label-free analysis of proteins using small sample volumes on a benchtop instrument - among academic researchers. "We are now pleased to offer our customers biosensors for the three most widely used peptide tags - HIS, GST and FLAG - among pharmaceutical and biotechnology scientists." The Octet family of products is based on ForteBio`s proprietary Bio-Layer Interferometry (BLI) technology. These instruments incorporate disposable optical Dip and Read biosensors that measure multiple interactions in parallel, without the use of detection agents. For single-sample analysis, ForteBio recently launched its BLItz instrument platform. The new platform revolutionizes the use of label-free protein analysis by making it more accessible and cost-effective for individual bench scientists in biotherapeutic discovery, process development and academic research. About ForteBio ForteBio is a division of Pall Life Sciences. ForteBio provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio`s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. For more information, visit www.fortebio.com. About Pall Life Sciences Pall Life Sciences, a division of Pall Corporation (NYSE:PLL), provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Its membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall Life Sciences is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall Life Sciences` technologies are also used in clinical institutions and the food and beverage industries. About Pall Corporation Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company`s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a "top green company" by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green. Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130212006653/en/ Doug Novarro Corporate Public Relations, Pall Corporation 516-801-9944 Doug_novarro@pall.com or Gemma Milan ForteBio 650-289-6800 Gemma_milan@pall.com Copyright Business Wire 2013
- Pope attacks mega-salaries and wealth gap in peace message
- Air strike kills 15 civilians in Yemen by mistake: officials
- Probation for drunk Texas teen driver who killed four sparks backlash
- Atheists face death in 13 countries, global discrimination: study
- South Africa admits error over 'schizophrenic' Mandela signer |